Mergers & acquisitions
After the transaction, it will be NovaBay’s largest shareholder with 6.6 million shares, 37% of the total.
Nanjing Legend Biotech received a very large $350M upfront payment from Janssen Biotech to partner Legend’s impressively effective CAR-T candidate.
Mallinckrodt picks up Sucampo’s Amitiza as well as two other pipeline compounds.
Roche got in some last-minute Christmas shopping, shelling out $1.7B for San Diego’s Ignyta.
Although it was an average year for mergers and acquisitions in the biopharma industry, it was a stronger year for IPOs.
Takeover whispers boosted long-standing target Shire to the top of the FTSE 100 as the pharma firm’s shares rallied on hopes of a mega deal bringing shareholders an early Christmas present.
Fresenius now expects its planned takeover of Akorn, a U.S. maker of liquid generic drugs, to be completed in early 2018 rather than this year, a spokesman for Fresenius said on Tuesday.
Ultragenyx CEO Emil Kakkis said the sale of the PRV will provide the company with an “important source of non-dilutive capital” that will be used to advance the company’s pipeline of rare and ultra-rare therapies.
Investors are salivating at the possibility of a hot merger-and-acquisition market in 2018.
PRESS RELEASES